維康藥業(300878.SZ):終止向不特定對象發行可轉換公司債券事項
格隆匯2月7日丨維康藥業(300878.SZ)公佈,公司於2024年2月7日召開第三屆董事會第十五次會議、第三屆監事會第十四次會議審議通過了《關於終止向不特定對象發行可轉換公司債券事項的議案》,決定終止向不特定對象發行可轉換公司債券(以下簡稱“本次發行”)事項。
公司在取得中國證監會批覆後,積極會同中介機構推進本次發行的各項工作。目前,綜合考慮宏觀經濟環境、資本市場環境及公司發展規劃等因素,經公司與中介機構溝通並審慎研究,決定終止向不特定對象發行可轉換公司債券事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.